Gibson, Dunn & Crutcher LLP advised 89bio, Inc. on its upsized public offering. 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher LLP is serving as legal counsel to Neurogene Inc. and Fenwick & West LLP is serving as legal counsel to Neoleukin Therapeutics,...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Mirum Pharmaceuticals, Cooley LLP is advising Travere Therapeutics, Inc. in the transaction. Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Apogee Therapeutics, Inc. in the offering. Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the pricing of its upsized initial public offering...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP is advising Spyre Therapeutics, Inc. in the transaction, while Cooley LLPis advising Aeglea. Aeglea BioTherapeutics, Inc. (“Aeglea”) (NASDAQ: AGLE), announced it has completed...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
You must be a Standard 1 Year member to access this content.
Guggenheim Securities, LLC is acting as financial advisor to Spectrum, and Gibson, Dunn & Crutcher LLP is serving as legal counsel. SVB Securities and H.C. Wainwright...
You must be a Standard 1 Year member to access this content.
